Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA521969
Max Phase: Preclinical
Molecular Formula: C23H21ClO6
Molecular Weight: 428.87
Molecule Type: Small molecule
Associated Items:
ID: ALA521969
Max Phase: Preclinical
Molecular Formula: C23H21ClO6
Molecular Weight: 428.87
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1cc(OC)c2c(c1Cl)O[C@]1(C2=O)C(OCc2ccccc2)=CC(=O)C[C@H]1C
Standard InChI: InChI=1S/C23H21ClO6/c1-13-9-15(25)10-18(29-12-14-7-5-4-6-8-14)23(13)22(26)19-16(27-2)11-17(28-3)20(24)21(19)30-23/h4-8,10-11,13H,9,12H2,1-3H3/t13-,23+/m1/s1
Standard InChI Key: LAWAOYZSUFCPKY-ZLOXQWCVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 428.87 | Molecular Weight (Monoisotopic): 428.1027 | AlogP: 4.38 | #Rotatable Bonds: 5 |
Polar Surface Area: 71.06 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.90 | CX LogD: 3.90 |
Aromatic Rings: 2 | Heavy Atoms: 30 | QED Weighted: 0.70 | Np Likeness Score: 1.25 |
1. Rønnest MH, Rebacz B, Markworth L, Terp AH, Larsen TO, Krämer A, Clausen MH.. (2009) Synthesis and structure-activity relationship of griseofulvin analogues as inhibitors of centrosomal clustering in cancer cells., 52 (10): [PMID:19402668] [10.1021/jm801517j] |
2. Rønnest MH, Raab MS, Anderhub S, Boesen S, Krämer A, Larsen TO, Clausen MH.. (2012) Disparate SAR data of griseofulvin analogues for the dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells., 55 (2): [PMID:22191585] [10.1021/jm200835c] |
3. Liéby-Muller F, Heudré Le Baliner Q, Grisoni S, Fournier E, Guilbaud N, Marion F.. (2015) Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives., 25 (10): [PMID:25872984] [10.1016/j.bmcl.2015.03.081] |
4. Petersen AB, Konotop G, Hanafiah NHM, Hammershøj P, Raab MS, Krämer A, Clausen MH.. (2016) Strategies for improving the solubility and metabolic stability of griseofulvin analogues., 116 [PMID:27061984] [10.1016/j.ejmech.2016.03.071] |
5. Petersen AB, Andersen NS, Konotop G, Hanafiah NH, Raab MS, Krämer A, Clausen MH.. (2017) Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability., 130 [PMID:28258034] [10.1016/j.ejmech.2017.02.055] |
Source(1):